Skip to content
Mirvetuximab soravtansine
Elahere (mirvetuximab soravtansine) is an antibody pharmaceutical. Mirvetuximab soravtansine was first approved as Elahere on 2022-11-14. It is used to treat fallopian tube neoplasms, ovarian epithelial carcinoma, and peritoneal neoplasms in the USA. It is known to target folate receptor alpha.
Download report
Favorite
Requested
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
digestive system diseasesD004066
urogenital diseasesD000091642
endocrine system diseasesD004700
Trade Name
FDA
EMA
Elahere
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Mirvetuximab soravtansine
Tradename
Proper name
Company
Number
Date
Products
Elaheremirvetuximab soravtansine-gynxImmunogenN-761310 RX2022-11-14
1 products
Labels
FDA
EMA
Brand Name
Status
Last Update
elahereBiologic Licensing Application2022-11-18
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
fallopian tube neoplasms—D005185—
ovarian epithelial carcinoma—D000077216—
peritoneal neoplasms—D010534—
Agency Specific
FDA
EMA
Expiration
Code
mirvetuximab soravtansine, Elahere, ImmunoGen, Inc.
2029-11-14Orphan excl.
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Fallopian tube neoplasmsD005185335——10
Ovarian neoplasmsD010051EFO_0003893C56222——6
Peritoneal neoplasmsD010534—24——6
Ovarian epithelial carcinomaD000077216114——5
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Endometrial neoplasmsD016889EFO_0004230—3———3
Triple negative breast neoplasmsD06472621———3
Breast neoplasmsD001943EFO_0003869C5011———2
Endometrioid carcinomaD018269—1———1
Acinar cell carcinomaD018267—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
CarcinosarcomaD0022961————1
NeoplasmsD009369C801————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMIRVETUXIMAB SORAVTANSINE
INNmirvetuximab soravtansine
Description
Mirvetuximab soravtansine, sold under the brand name Elahere, is a medication used as a treatment for fallopian tube cancer or primary peritoneal cancer. Mirvetuximab soravtansine is a folate receptor alpha directed antibody and microtubule inhibitor conjugate.
Classification
Antibody
Drug classmonoclonal antibodies; maytansinoid derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID1453084-37-1
RxCUI—
ChEMBL IDCHEMBL3545132
ChEBI ID—
PubChem CID—
DrugBankDB12489
UNII ID98DE7VN88D (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
FOLR1
FOLR1
Organism
Homo sapiens
Gene name
FOLR1
Gene synonyms
FOLR
NCBI Gene ID
2348
Protein name
folate receptor alpha
Protein synonyms
Adult folate-binding protein, FBP, folate binding protein, Folate receptor 1, folate receptor 1 (adult), Folate receptor, adult, FR-alpha, KB cells FBP, Ovarian tumor-associated antigen MOv18
Uniprot ID
Q9UCT2
Mouse ortholog
Folr1 (14275)
folate receptor alpha (Q9R222)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 252 documents
View more details
Safety
Black-box Warning
Black-box warning for: Elahere
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
7 adverse events reported
View more details